drugset
drugset / Trial / NCT03009396

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

NCT03009396 ↗

Phase 3 Completed 54 enrolled RedHill Biopharma Limited
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open label extension to the RHB-104-01 Study.

Timeline

Start
2017-03-18
Primary completion
2018-11-13
Completion
2019-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 95 mg —
Subject Clofazimine Small molecule 10 mg —
Subject Rifabutin Small molecule 45 mg —

Indications

Crohn disease